Latest Safety News

Starpharma launches a fully underwritten $32 million entitlement offer to fund the Phase 1 trial of its DEP® HER2-Lutetium radiopharmaceutical and accelerate its targeted oncology asset development.

29Metals reported a mixed June quarter with lower copper but higher zinc production at Golden Grove, steady safety metrics, and ongoing development progress including Xantho Extended mining restart and Gossan Valley first ore on track. Capricorn Copper's restart hinges on regulatory approval and a definitive feasibility study due by year-end.

Rio Tinto reported a 3% year-on-year increase in copper equivalent production for H1 2026, driven by Oyu Tolgoi’s 31% growth and record iron ore output in the Pilbara, while maintaining full-year guidance amid geopolitical headwinds.

Mesoblast has completed treatment of 300 patients in its pivotal Phase 3 trial for rexlemestrocel-L, targeting chronic low back pain due to degenerative disc disease, with topline results expected mid-2027.

Polymetals Resources accelerated production and revenue growth in the June quarter, underpinned by high-grade drilling results that suggest a smaller historic collapse and expanded resource potential at the Endeavor Mine.

Neurotech International has secured FDA clearance for its Investigational New Drug application for NTI164, enabling clinical development in the US and advancing its global registration and commercialisation plans.

Coronado Global Resources has promoted CFO Barrie van der Merwe to CEO, tasking him with steering the coal miner back to profitability and lowering its debt burden.

Paradigm Biopharmaceuticals has secured US$3 million in its latest tranche under a US$27 million convertible note facility, bolstering funding for its global Phase 3 trial of injectable pentosan polysulfate sodium in knee osteoarthritis.

Biotron Limited has met the first milestone in its Sedarex acquisition by securing pivotal regulatory feedback from the European Medicines Agency, charting a clearer path for its next-generation anaesthetic SedRx.

Vectus Biosystems has appointed Cardinal Health Regulatory Services as its US regulatory agent to manage FDA submissions for its lead fibrosis drug VB0004, marking a pivotal step towards clinical development in the US.

Immutep’s INSIGHT-003 trial shows promising overall survival in first-line non-squamous NSCLC, yet the Phase III TACTI-004 trial was discontinued following a futility analysis. Ongoing root cause investigations aim to clarify the divergent outcomes.

CLINUVEL Pharmaceuticals secures Canadian marketing approval for SCENESSE®, expanding access to the only approved systemic photoprotective treatment for erythropoietic protoporphyria (EPP).